Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Product Development

Low-stakes 2018 deal with Regeneron leads to bump for Kiniksa on pericarditis readout

June 30, 2020 12:51 AM UTC

Pivotal data for rilonacept in recurrent pericarditis put Kiniksa on track to bring its first program to market and gain rights from Regeneron to additional indications.

Kiniksa Pharmaceuticals Ltd. (NASDAQ:KNSA) shares rose $2.97 (13%) to $26 Monday, adding $173.9 million to the company's market cap, on the readout from the Phase III RHAPSODY trial of rilonacept...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Kiniksa Pharmaceuticals Ltd.

BCIQ Target Profiles

Interleukin-1 (IL-1)